Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PERA-B is a combination generic medication marketed by the Indian pharmaceutical company C-PHARM. It is formulated as an oral tablet or syrup and typically contains a combination of paracetamol (acetaminophen) and bromhexine. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, primarily through the inhibition of cyclooxygenase enzymes (COX-1 and COX-2) in the central nervous system. Bromhexine acts as a mucolytic agent that increases the production of serous bronchial secretions and reduces mucus viscosity by dissolving mucopolysaccharide fibers, thereby facilitating the clearance of phlegm. The product is intended for the symptomatic treatment of fever, pain, and productive cough associated with respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PERA-B.